Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies por Walter Suárez Carmona | Feb 3, 2025
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? por Walter Suárez Carmona | Feb 3, 2025
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? por Walter Suárez Carmona | Feb 3, 2025
Tirzepatide for Metabolic Dysfunction– Associated Steatohepatitis with Liver Fibrosis por Walter Suárez Carmona | Feb 3, 2025
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis por Walter Suárez Carmona | Feb 3, 2025
